Media
On this page, we highlight information of particular relevance for the media, including news, events and featured information for journalists interested in the evaluation and safety monitoring of medicines in the European Union.
For more information and details relevant for media, see our News and events section.
For enquiries from media, please contact the EMA press office.
Featured information for journalists
EMA communication activities: 2024 survey results
We asked stakeholders for feedback on our external communication activities via a bi-annual survey disseminated in May 2024. The results are available in a newly-published report. They help us to establish baselines and targets to measure progress, analyse trends and address areas for improvement.
EU agencies promoting a One Health approach
EMA and other scientific EU agencies responsible for human, animal health and environmental protection have established a task force to coordinate activities and share information, promoting a joined-up One Health approach. A paper is available containing more details.
2022 annual report
Navigate through the digital report to view interviews, short videos and an interactive timeline of the Agency’s main activities in 2022. Read the traditional PDF version to see additional figures and statistics on EMA's regulatory procedures and activities.
Human medicines: highlights of 2022
In 2022, EMA recommended 89 medicines for marketing authorisation. Of these, 41 had a new active substance which had never been authorised in the European Union before. These included two vaccines and two treatments for COVID-19.
Veterinary medicines: highlights of 2022
In 2022, EMA recommended 10 medicines for marketing authorisation. Of these, three had a new active substance. Two are vaccines, including one new biotechnological vaccine.
European medicines agencies network strategy to 2025
The strategy sets out how the network will continue to enable the supply of safe and effective medicines, in the face of developments in science, medicine, digital technologies, globalisation and emerging health threats, such as the COVID-19 pandemic.
Latest news
Tepezza significantly improves symptoms for patients with moderate-to-severe TED
Duvyzat can be used in a wide patient population from the age of six
16 new medicines recommended for approval; another ten medicines recommended for extension of their therapeutic indications
The European Medicines Agency's (EMA) office is closed from 18:00 on 16 April 2025 to 08:30 on 22 April 2025
Publications of interest
EMA's 2023 annual report
Navigate through the digital report to view interviews, short videos and an interactive timeline of the Agency’s main activities in 2023. Read the traditional PDF version to see additional figures and statistics on EMA's regulatory procedures and activities.
Video: Working for every patient in Europe
Watch our short video for a quick and easy explanation of who EMA is and what it does. (video in English, with subtitles in 24 different languages).